Hikma Pharmaceuticals Share Price (HIK)
| Bid price | 1,673.00 | Open price | 0.00 |
|---|---|---|---|
| Ask price | 1,673.50 | Prev close | 1,673.50 |
| High price | 0.00 | Spread | 0.00% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Hikma Pharmaceuticals Share Price Chart
Register now for FREE Hikma Pharmaceuticals share price charts
Hikma Pharmaceuticals Share Price Information
| Name | Hikma Pharmaceuticals | Epic | HIK |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00B0LCW083 |
| Activites | Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. | Index | FTSE 100 |
Hikma Pharmaceuticals Key Numbers
| Latest Share Price (p) | 0.00 | Net Gearing (%) | 48.20 |
|---|---|---|---|
| Market Capitalisation (£m) | 4,149.46 | Gross Gearing (%) | 54.90 |
| Shares in issue (m) | 241.46 | Debt Ratio | 41.03 |
| P/E Ratio | -4.89 | Debt-to-Equity Ratio | 0.57 |
| Total dividends per share (p) | 34.00 | Assets / Equity Ratio | 2.22 |
| Dividend Yield (%) | 1.31 | Price to book value | 2.72 |
| Dividend cover (x) | 0.00 | ROCE (%) | -28.48 |
| Earning per share (p) | -351.80 | EPS Growth (%) | -629.02 |
| 52 week high / low | 2,089.00 / 814.20 | DPS Growth (%) | 3.03 |
Hikma Pharmaceuticals Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 30/05/2018 | BUY | Sigurdur Olafsson | CEO | 20,000 |
| 23/05/2018 | BUY | John Castellani | NED | 1,000 |
| 15/05/2018 | TIN | Mazen Darwazah | ED | 20,000 |
| 15/05/2018 | TIN | Said Darwazah | CH | 27,000 |
| 19/03/2018 | TIN | Mazen Darwazah | ED | 38,501 |
Hikma Pharmaceuticals Company News
Director/PDMR Shareholding
RNS Number : 6285P Hikma Pharmaceuticals Plc 11 February 2019 Hikma Pharmaceuticals PLC Notification and public disclosure of transactions by persons discharging managerial responsibilities Said Darwazah 1 Details of the person discharging managerial...
Total Voting Rights
RNS Number : 8912O Hikma Pharmaceuticals Plc 01 February 2019 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 1 February 2019 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC...
Hikma Pharmaceuticals US unit launches injectable cancer treatment
Hikma Pharmaceuticals said its US unit had launched its cancer treatment Mitomycin for injection. The treatment was not recommended as single-agent, primary therapy but had been shown to be useful in treating disseminated adenocarcinoma of the stomach or pancreas in proven combinations with...
More Hikma Pharmaceuticals Company News >>
Register now for FREE Hikma Pharmaceuticals company news
Hikma Pharmaceuticals Share Price Discussions
Hikma Pharmaceuticals (HIK)
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions